Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies

被引:0
|
作者
von Maltitz, Pascal [1 ]
Wettstein, Lukas [1 ]
Weil, Tatjana [1 ]
Schommers, Philipp [2 ,3 ,4 ,5 ,6 ,7 ]
Klein, Florian [2 ,3 ,4 ,5 ]
Muench, Jan [1 ]
机构
[1] Univ Ulm Med Ctr, Inst Mol Virol, Ulm, Germany
[2] Univ Cologne, Inst Virol, Fac Med, Lab Expt Immunol, Cologne, Germany
[3] Univ Hosp Cologne, Cologne, Germany
[4] German Ctr Infect Res, Cologne, Germany
[5] Ctr Mol Med Cologne CMMC, Cologne, Germany
[6] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany
[7] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
关键词
bNAb; HIV-1; semen; microbicide; DOUBLE-BLIND; VAGINAL GEL; PREVENTION; MICROBICIDES; PHASE-3;
D O I
10.1128/jvi.01190-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Topically applied microbicides may play a critical role in preventing sexual transmission of human immunodeficiency virus type 1 (HIV-1); however, their efficacy can be compromised by amyloid fibrils present in semen, which significantly increase HIV-1 infectivity. This phenomenon may have contributed to the failure of most microbicide candidates in clinical settings. Understanding the impact of semen on microbicide effectiveness is thus crucial. In our study, we evaluated the influence of semen on the neutralizing activity of broadly neutralizing antibodies (bNAbs), including PG16, PGT121, 10-1074, 3BNC117, and VRC01, which are potential microbicide candidates. We found that semen enhances infection of HIV-1 transmitted/founder viruses but only marginally affects the neutralizing activity of tested antibodies, suggesting their potential for microbicide application. Our findings underscore the need to consider semen-mediated enhancement when evaluating and developing microbicides and highlight the potential of incorporating HIV-1 bNAbs in formulations to enhance efficacy and mitigate HIV-1 transmission during sexual encounters.IMPORTANCEThis study examined the impact of semen on the development of microbicides, substances used to prevent the transmission of HIV-1 during sexual activity. Semen contains certain components that can render the virus more infectious, posing a challenge to microbicide effectiveness. Researchers specifically investigated the effect of semen on a group of powerful antibodies called broadly neutralizing antibodies, which can neutralize a large spectrum of different HIV-1 variants. The results revealed that semen only had a minimal effect on the antibodies' ability to neutralize the virus. This is promising because it suggests that these antibodies could still be effective in microbicides, even in the presence of semen. Understanding this interaction is crucial for developing better strategies to prevent HIV-1 transmission. By incorporating the knowledge gained from this study, scientists can now focus on creating microbicides that consider the impact of semen, bringing us closer to more effective prevention methods. This study examined the impact of semen on the development of microbicides, substances used to prevent the transmission of HIV-1 during sexual activity. Semen contains certain components that can render the virus more infectious, posing a challenge to microbicide effectiveness. Researchers specifically investigated the effect of semen on a group of powerful antibodies called broadly neutralizing antibodies, which can neutralize a large spectrum of different HIV-1 variants. The results revealed that semen only had a minimal effect on the antibodies' ability to neutralize the virus. This is promising because it suggests that these antibodies could still be effective in microbicides, even in the presence of semen. Understanding this interaction is crucial for developing better strategies to prevent HIV-1 transmission. By incorporating the knowledge gained from this study, scientists can now focus on creating microbicides that consider the impact of semen, bringing us closer to more effective prevention methods.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies
    Zhang, Zhiqing
    Li, Shaowei
    Gu, Ying
    Xia, Ningshao
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (11)
  • [2] Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted/founder sensitivity to broadly neutralizing antibodies
    Parthasarathy, Durgadevi
    Pothula, Karunakar Reddy
    Ratnapriya, Sneha
    Cervera Benet, Hector
    Parsons, Ruth
    Huang, Xiao
    Sammour, Salam
    Janowska, Katarzyna
    Harris, Miranda
    Sodroski, Joseph
    Acharya, Priyamvada
    Herschhorn, Alon
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [3] Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
    Bar-On, Yotam
    Gruell, Henning
    Schoofs, Till
    Pai, Joy A.
    Nogueira, Lilian
    Butler, Allison L.
    Millard, Katrina
    Lehmann, Clara
    Suarez, Isabelle
    Oliveira, Thiago Y.
    Karagounis, Theodora
    Cohen, Yehuda Z.
    Wyen, Christoph
    Scholten, Stefan
    Handl, Lisa
    Belblidia, Shiraz
    Dizon, Juan P.
    Vehreschild, Joerg J.
    Witmer-Pack, Maggi
    Shimeliovich, Irina
    Jain, Kanika
    Fiddike, Kerstin
    Seaton, Kelly E.
    Yates, Nicole L.
    Horowitz, Jill
    Gulick, Roy M.
    Pfeifer, Nico
    Tomaras, Georgia D.
    Seaman, Michael S.
    Faetkenheuer, Gerd
    Caskey, Marina
    Klein, Florian
    Nussenzweig, Michel C.
    NATURE MEDICINE, 2018, 24 (11) : 1701 - +
  • [4] Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
    Yotam Bar-On
    Henning Gruell
    Till Schoofs
    Joy A. Pai
    Lilian Nogueira
    Allison L. Butler
    Katrina Millard
    Clara Lehmann
    Isabelle Suárez
    Thiago Y. Oliveira
    Theodora Karagounis
    Yehuda Z. Cohen
    Christoph Wyen
    Stefan Scholten
    Lisa Handl
    Shiraz Belblidia
    Juan P. Dizon
    Jörg J. Vehreschild
    Maggi Witmer-Pack
    Irina Shimeliovich
    Kanika Jain
    Kerstin Fiddike
    Kelly E. Seaton
    Nicole L. Yates
    Jill Horowitz
    Roy M. Gulick
    Nico Pfeifer
    Georgia D. Tomaras
    Michael S. Seaman
    Gerd Fätkenheuer
    Marina Caskey
    Florian Klein
    Michel C. Nussenzweig
    Nature Medicine, 2018, 24 : 1701 - 1707
  • [5] Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
    Cohen, Yehuda Z.
    Caskey, Marina
    CURRENT OPINION IN HIV AND AIDS, 2018, 13 (04) : 366 - 373
  • [6] Broadly neutralizing antibodies: An approach to control HIV-1 infection
    Yaseen, Mahmoud Mohammad
    Yaseen, Mohammad Mahmoud
    Alqudah, Mohammad Ali
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2017, 36 (01) : 31 - 40
  • [7] Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
    Awan, Seemal F.
    Happe, Myra
    Hofstetter, Amelia R.
    Gama, Lucio
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (04) : 247 - 257
  • [8] Role of Broadly Neutralizing Antibodies in the Controlling of HIV-1 Infection
    Yildirmak, Taner
    KLIMIK JOURNAL, 2019, 32 (02) : 112 - 116
  • [9] Evolution of HIV-1 Transmitted/Founder Viruses Results in the Formation of Epitopes for Later Broadly Cross-Neutralizing Antibodies
    Moore, P. L.
    Gray, E. S.
    Hermanus, T.
    Sheward, D.
    Tumba, N.
    Wibmer, C. K.
    Bhiman, J.
    Sibeko, S.
    Karim, S. S. Abdool
    Williamson, C.
    Morris, L.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A29 - A29
  • [10] Broadly neutralizing antibodies to prevent HIV-1
    Cohen, Myron S.
    Corey, Lawrence
    SCIENCE, 2017, 358 (6359) : 46 - 47